Rathnam Chaguturu joins SRI International

Monday, January 30, 2012 02:25 PM

Rathnam Chaguturu, Ph.D., has joined SRI International's Center for Advanced Drug Research (CADRE) as senior director of exploratory research. Chaguturu will partner with SRI's drug discovery and development teams and expand collaborative research relationships with academia, disease foundations, nonprofits and government agencies.

Previously, Chaguturu held director positions at Sierra Sciences in drug discovery and at the University of Kansas in High Throughput Screening Laboratory. He also led discovery research efforts at FMC for more than 20 years, where he was instrumental in designing the industry-first Zymark robotic screening platform for lead discovery.

Chaguturu has authored more than 50 research publications, holds 11 U.S. patents and is editor-in-chief of the journal Combinatorial Chemistry and High Throughput Screening. He is also one of the founding members of the Society for Biomolecular Sciences and the founding president of the International Chemical Biology Society.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs